The HIV vaccine saga

Medical Immunology

Volumn 2, Issue , 2003, Pages

  Smith, Kendall A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; DNA VACCINE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; NEUTRALIZING ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY TITER; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CELLULAR IMMUNITY; DISEASE TRANSMISSION; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION RISK; MAJOR HISTOCOMPATIBILITY COMPLEX; MEDICAL ETHICS; NONHUMAN; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

EID: 0042533755     PISSN: 14769433     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-9433-2-1     Document Type: Article

References (35)

1. Montagnier L Historical essay. A history of HIV discovery. Science 2002, 298:1727-8
2. Gallo R Historical essay. The early years of HIV/AIDS. Science 2002, 298:1728-30
3. Smith K Medical immunology: a new journal for a new subspecialty. Med Immunol 2002, 1:1
4. Jenner E An Inquiry into the Causes and Effects of Variolae Vaccinae, a Disease Discovered in Some Western Counties of England. London: Sampson Low; 1798,
5. Kwong P, Doyle M, Casper D, Cicala C, Leavitt S, Majeed S, Steenbeke T, Venturi M, Chaiken I and Fung M HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002, 420:678-82
6. Ketas T, Frank I, Klasse P, Sullivan B, Gardner J, Spenlehauer C, Nesin M, Olson W, Moore J and Pope M Human Immunodeficiency Virus Type 1 Attachment, Coreceptor, and Fusion Inhibitors Are Active against both Direct and trans Infection of Primary Cells. J Virol 2003, 77:2762-2767
7. Yang X, Farzan M, Wyatt R and Sodroski J Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 2000, 74:5716-25
8. Barre-Sinoussi F, Chermann J, Rey F, Nugeyre M, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F and Rouzioux C Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220:868-71
9. Smith KA, Favata MF and Oroszlan S Production and characterization of monoclonal antibodies to human interleukin 2: strategy and tactics. J Immunol 1983, 131:1808-15
10. Taniguchi T, Matsui H, Fujita T, Takaoka C, Kashima N, Yoshimoto R and Hamuro J Structure and expression of a cloned cDNA for human interleukin-2. Nature 1983, 302:305-10
11. Cantrell DA and Smith KA The interleukin-2 T-cell system: a new cell growth model. Science 1984, 224:1312-6
12. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, Miller JD, Slansky J and Ahmed R Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998, 8:177-87
13. Flynn KJ, Belz GT, Altman JD, Ahmed R, Woodland DL and Doherty PC Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 1998, 8:683-91
14. Butz EA and Bevan MJ Massive expansion of antigen-specific CD8+ T cells during an acute virus infection. Immunity 1998, 8:167-75
15. Gallimore A, Glithero A, Godkin A, Tissot AC, Pluckthun A, Elliott T, Hengartner H and Zinkernagel R Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med 1998, 187:1383-93
16. Openshaw P, Murphy EE, Hosken NA, Maino V, Davis K, Murphy K and O'Garra A Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations. J Exp Med 1995, 182:1357-67
17. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R and Chisari FV Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996, 4:25-36
18. Smith K To cure chronic HIV infection, a new strategy is needed. Current Opinion in Immunology 2001, 13:617-624
19. Reimann K, Li J, Voss G, Lekutis C, Tenner-Racz K, Racz P, Lin W, Montefiori D, Lee-Parritz D and Lu Y An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J Virol 1996, 70:3198-206
20. Barouch D, Santra S, Schmitz J, Kuroda M, Fu T, Wagner W, Bilska M, Craiu A, Zheng X and Krivulka G Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000, 290:486-92
21. Barouch D, Santra S, Kuroda M, Schmitz J, Plishka R, Buckler-White A, Gaitan A, Zin R, Nam J and Wyatt L Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol 2001, 75:5151-8
22. Shiver J, Fu T, Chen L, Casimiro D, Davies M, Evans R, Zhang Z, Simon A, Trigona W and Dubey S Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002, 415:331-5
23. Barouch D, Kunstman J, Kuroda M, Schmitz J, Santra S, Peyerl F, Krivulka G, Beaudry K, Lifton M and Gorgone D Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002, 415:335-9
24. Willey R, Byrum R, Piatak M, Kim Y, Cho M, Rossio JJ, Bess JJ, Igarashi T, Endo Y and Arthur L Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles. J Virol 2003, 77:1163-74
25. Feinberg M and Moore J AIDS vaccine models: challenging challenge viruses. Nat Med 2002, 8:207-10
26. Specter M The vaccine. The New Yorker 2003, 54-65
27. Cohen J Thai AIDS trial faces delay. Science 2003, 299:323
28. Rosenberg E, Altfeld M, Poon S, Phillips M, Wilkes B, Eldridge R, Robbins G, D'Aquila R, Goulder P and Walker B Immune control of HIV-1 after early treatment of acute infection. Nature 2000, 407:523-526
29. Chun T, Davey R, Engel D, Lane H and Fauci A Re-emergence of HIV after stopping therapy. Nature 1999, 401:874-5
30. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F and Flexner C Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999, 5:512-7
31. Smith K, Jacobson E, Sohn T, Warren D, Emert R and Giordano M In vivo assessment of antiviral reactivity in chronic HIV infection. HIV Clinical Trials 2000, 1:16-22
32. Little SJ, McLean AR, Spina CA, Richman DD and Havlir DV Viral dynamics of acute HIV-1 infection. J Exp Med 1999, 190:841-50
33. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA and Hahn BH Viral dynamics in human immunodeficiency virus type 1 infection [see comments]. Nature 1995, 373:117-22
34. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM and Markowitz M Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection [see comments]. Nature 1995, 373:123-6
35. Smith K Optimal clinical trial designs for immune-based therapies in persistent viral infections. Med Immunol 2002, 1:4